tsDMARDlääkkeistä

tsDMARDlääkkeet, or targeted synthetic disease-modifying antirheumatic drugs, represent a class of medications used to treat inflammatory autoimmune diseases, most notably rheumatoid arthritis. Unlike traditional DMARDs, tsDMARDs are designed to selectively inhibit specific molecules involved in the inflammatory pathways of these conditions. The most prominent group within tsDMARDs are the Janus kinase (JAK) inhibitors. JAKs are intracellular enzymes that play a crucial role in signaling pathways for cytokines, which are proteins that promote inflammation. By blocking JAKs, these drugs interfere with the signals that drive inflammation and joint damage.

The development of tsDMARDs marked a significant advancement in the management of inflammatory diseases, offering a more targeted approach compared to broader immunosuppressants. They are typically administered orally, which can be an advantage for patient convenience. While effective in reducing inflammation, pain, and preventing joint destruction, tsDMARDs are associated with potential side effects. These can include an increased risk of infections, particularly serious ones, due to their impact on the immune system. Other concerns may involve changes in blood counts, lipid levels, and gastrointestinal issues. Therefore, careful monitoring by a healthcare professional is essential when using these medications. They are generally prescribed for patients who have not responded adequately to conventional DMARDs or biologic DMARDs.